EyePoint, Inc.
EYPTHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeEyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. With a market capitalization of $1.12B, it sits in small-cap territory. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Market Cap
$1.12B
Beta
1.74
P/E (TTM)
—
P/E (Fwd)
-4.49
EPS (TTM)
$-3.51
EPS (Fwd)
$-2.96
ROE
-102.7%
ROA
-54.1%
Cash
$45.3M
Total Debt
$17.6M
Free CF
-$168.7M
52W Change
27.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $45.3M in cash comfortably exceeding the $17.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$168.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -102.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $41.4M (2022) to $31.4M (2025), a 24% decline worth watching.
EyePoint, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, EYPT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for EyePoint, Inc. and its sector.